Research ArticleExperimental Studies

Continuous Administration of the Somatostatin Structural Derivative /TT-232/ by Subcutaneously Implanted Osmotic Pump Improves the Efficacy and Potency of Antitumor Therapy in Different Mouse and Human Tumor Models

M. TEJEDA, D. GAAL, L. HULLÁN, O. CSUKA, R. SCHWAB, O. SZOKOLOCZI and G.Y. KÉRI
Anticancer Research September 2008, 28 (5A) 2769-2774;

Article Information

vol. 28 no. 5A 2769-2774
PMID 
19035308
Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received February 21, 2008
  • Revision received July 7, 2008
  • Accepted July 8, 2008
  • Published online September 1, 2008.
Copyright & Usage 
Copyright© 2008 International Institute of Anticaner Research (Dr. John G. Delinassios), All rights reserved

Author Information

  1. M. TEJEDA1,
  2. D. GAAL1,
  3. L. HULLÁN1,
  4. O. CSUKA1,
  5. R. SCHWAB2,
  6. O. SZOKOLOCZI2 and
  7. G.Y. KÉRI3
  1. 1National Institute of Oncology, Budapest
  2. 2Rational Drug Dosing Laboratories (CRC), Semmelweis University, Budapest
  3. 3Peptide Biochemistry Research Group of the Hungarian Academy of Sciences, Department of Medical Chemistry, Semmelweis University, Budapest, Hungary
  1. Correspondence to: Miguel Tejeda, Ph.D., National Institute of Oncology, 1122 Ráth Gy. u. 7-9, Budapest, Hungary. Tel: +36 12248600, Fax: +36 12248620

Statistics from Altmetric.com

Cited By...

Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Continuous Administration of the Somatostatin Structural Derivative /TT-232/ by Subcutaneously Implanted Osmotic Pump Improves the Efficacy and Potency of Antitumor Therapy in Different Mouse and Human Tumor Models
M. TEJEDA, D. GAAL, L. HULLÁN, O. CSUKA, R. SCHWAB, O. SZOKOLOCZI, G.Y. KÉRI
Anticancer Research Sep 2008, 28 (5A) 2769-2774;
Twitter logo Facebook logo Mendeley logo

Jump to section